LITTLE KNOWN FACTS ABOUT AGO TUMOR.

Molecular typing is predicated on molecular genetic tests and isn't however routinely available. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 could possibly be valuab